Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

Model scores of the 29,894 trials active now.

Model score 29% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-09-15. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cell lunglung cancersmall cellnon smallnsclc
  Phrases that lowered it: maleparticipantpartnermethodscondom
• Sponsor's past termination rate: 26.2% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 46.2% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 90.0% (raises risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 216 (lowers risk) · Sponsor's track record
• Responsible party: sponsor (lowers risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Number of arms: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer NCT03292133 · started 2017 · scored riskier than 96% of active trials terminated
• A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) NCT04965090 · started 2021 · scored riskier than 47% of active trials completed
• Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies NCT02620839 · started 2016 · scored riskier than 44% of active trials terminated
• Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer NCT04971187 · started 2021 · scored riskier than 76% of active trials terminated
• Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer NCT02503358 · started 2016 · scored riskier than 90% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.